NCKAP1 is a Prognostic Biomarker for Inhibition of Cell Growth in Clear Cell Renal Cell Carcinoma

• DOI: 10.3389/fgene.2022.764957
• Publication Date: 2022-07-26T06:37:27Z
• Authors: Jiasheng Chen; Jianzhang Ge; Wancong Zhang; Xuqi Xie; Xiaoping Zhong; Shijie Tang
• Keywords: 0303 health sciences; 03 medical and health sciences; Nckap1; Genetics; biomarkers; prognosis; progression; clear cell renal cell carcinoma; QH426-470; 3. Good health

Background: Clear cell renal carcinoma (ccRCC) is the most frequent type of kidney cancer. Nck-associated protein 1 (NCKAP1) associated with poor prognosis and tumor progression in several cancer types, but function prognostic value NCKAP1 ccRCC remain poorly understood. Methods: Using Ualcan database, we evaluated correlation between expression clinical features ccRCC. These data were validated by immunohistochemical staining for a cohort patients. We assessed using GEPIA2 survival analysis. was characterized vitro vivo NCKAP1-overexpression ACHN lines. The LinkedOmics GSCALite databases used to investigate identify potential NCKAP1-targeted medicines that may play role treatment impact on immune infiltration also evaluated. Results: significantly downregulated correlated advanced clinicopathological prognosis. Overexpression cells reduced proliferation, invasion migration capacity inhibited growth vivo. According LinkedOmics, TIMER databases, related genes primarily ribosomal signaling, oxidative phosphorylation, TGF-β, EMT-related signaling pathways. shown positively correlate biomarkers, checkpoints ccRCCs. Conclusions: vital tumor-suppressive potentially useful biomarker.